<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828798</url>
  </required_header>
  <id_info>
    <org_study_id>99920724</org_study_id>
    <nct_id>NCT04828798</nct_id>
  </id_info>
  <brief_title>Directional Versus Nondirectional DBS for ET</brief_title>
  <official_title>Directional Versus Nondirectional Deep Brain Stimulation of the VIM Thalamic Nucleus for Essential Tremor: Assessment of Therapeutic Window, Speech, Gait and Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center (OHSU) proof of concept trial to demonstrate that directional&#xD;
      deep brain stimulation (DBS) creates a larger therapeutic window for the treatment of&#xD;
      essential tremor (ET), effectively treats ET, and minimizes effects on speech, gait and&#xD;
      balance compared to nondirectional DBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:&#xD;
&#xD;
        1. To compare the therapeutic window (TW) of directional versus nondirectional deep brain&#xD;
           stimulation for treatment of tremor.&#xD;
&#xD;
           Hypothesis: directional DBS will result in a wider TW than nondirectional DBS.&#xD;
&#xD;
        2. To compare the effects of directional versus nondirectional DBS on speech Hypothesis:&#xD;
           Objective and subjective speech impairment will occur to a greater extent in&#xD;
           nondirectional DBS versus directional DBS optimized for tremor control.&#xD;
&#xD;
        3. To compare the effects of directional versus nondirectional DBS on balance and gait&#xD;
           Hypothesis: Objective and subjective balance and gait impairment will occur to a greater&#xD;
           extent in nondirectional DBS versus directional DBS optimized for tremor control.&#xD;
&#xD;
        4. To assess efficacy for tremor of nondirectional and directional DBS in an optimized&#xD;
           programming configuration Hypothesis: both directional and nondirectional DBS will&#xD;
           significantly improve tremor compared to baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">February 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blinded crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic window</measure>
    <time_frame>3 months</time_frame>
    <description>Range of therapeutic current from clinical improvement to side effect threshold, measured in milliamps, within a range of 0.0 to 5.0 milliamps</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of tremor</measure>
    <time_frame>3 months</time_frame>
    <description>Change in The Essential Tremor Rating Scale (TETRAS) combined score. Range = 0 to112. Higher score = worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of directional versus nondirectional DBS on self perception of speech</measure>
    <time_frame>3 months</time_frame>
    <description>Self Perception of speech: Subjects will rate their &quot;ability to speak&quot; on a VAS (from 0 [normal] to 100 mm [worst]) in each condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of directional versus nondirectional DBS on balance and gait</measure>
    <time_frame>3 months</time_frame>
    <description>The Activities-specific Balance Confidence (ABC) scale is a 16-item self-report measure in which participants rate their balance confidence on a 0-100 scale (0 = 0 no confidence, 100 = 100 complete confidence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of directional versus nondirectional DBS on perceptual assessment of voice and speech</measure>
    <time_frame>3 months</time_frame>
    <description>Perceptual assessment of voice and speech will be completed with listeners judging a reading sample using a 100mm Visual Analog Scale (VAS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Directional deep brain stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation delivered in a directional manner within an axial plane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nondirectional deep brain stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation delivered in a nondirectional manner within an axial plane</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep brain stimulation of the VIM Thalamic nuclei</intervention_name>
    <description>Deep brain stimulation of the thalamus, in a directional and nondirectional manner</description>
    <arm_group_label>Directional deep brain stimulation</arm_group_label>
    <arm_group_label>Nondirectional deep brain stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A tremor syndrome of bilateral upper limb action tremor with at least 3 years'&#xD;
             duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have decided not to receive DBS for control of their&#xD;
             medication-refractory essential tremor.&#xD;
&#xD;
          -  Patients with secondary tremor (ie not Essential Tremor), such as side effects from&#xD;
             medications, secondary to another identified neurologic disease (eg multiple&#xD;
             sclerosis, -----Parkinson's disease, dystonia).&#xD;
&#xD;
          -  Prior history of deep brain stimulation.&#xD;
&#xD;
          -  Prior history of thalamotomy.&#xD;
&#xD;
          -  A history or signs of dystonia, ataxia or parkinsonism.&#xD;
&#xD;
          -  Task specific tremor.&#xD;
&#xD;
          -  Orthostatic tremor.&#xD;
&#xD;
          -  Patients with cardiac pacemakers, defibrillators, or neurostimulators.&#xD;
&#xD;
          -  Patients who require MRI, ECT, rTMS, or diathermy.&#xD;
&#xD;
          -  Subjects with other type of neurological disease or injury.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zoe Fanning</last_name>
    <phone>503-494-7772</phone>
    <email>fanningz@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Fanning</last_name>
      <phone>503-494-7772</phone>
      <email>fanningz@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Matthew Brodsky</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

